US2015239849A1PendingUtilityA1
Inhibitors of beta-secretase
Est. expiryAug 27, 2032(~6.1 yrs left)· nominal 20-yr term from priority
Inventors:Yuri BukhtiyarovSalvacion CacatianLawrence Wayne DillardKlaus FuchsLanqi JiaDeepak S. LalaAngel Morales-RamosSuresh B. SinghShankar VenkatramanZhenrong XuJing YuanYi ZhaoYajun ZhengCornelia Dorner-CiossekUlrike GrossNiklas HeineAchim Sauer
A61P 43/00A61P 25/16A61P 27/02A61P 25/28A61P 27/06A61P 25/00C07D 403/14C07C 255/59C07C 2603/97C07C 313/06C07C 49/747C07C 229/50C07C 49/755C07D 401/14C07C 2603/94C07C 331/26C07D 235/02C07D 403/04C07D 401/06A61K 31/506A61K 31/4184C07D 403/06C07D 405/06A61K 31/4439C07C 2103/97
40
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.
Claims
exact text as granted — not AI-modified1 - 13 . (canceled)
14 . A method of treating a BACE1 mediated disorder or disease in a subject, comprising administering to the subject an effective amount of a compound represented by a structural formula selected from:
or a pharmaceutically acceptable salt thereof.
15 . The method of claim 14 , wherein the BACE1 mediated disorder or disease is selected from the group consisting of neurodegenerative disorder, cognitive decline, cognitive impairment, dementia and disease characterized by the production of β-amyloid deposits or neurofibrillary tangles.
16 . The method of claim 15 , wherein the disorder or disease is selected from the group consisting of Alzheimer's disease, Trisomy 21 (Down Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), senile dementia, cerebral amyloid angiopathy, degenerative dementia, dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease, dry age related macular degeneration (AMD), and glaucoma.
17 - 18 . (canceled)
19 . A compound selected from the group consisting of:
or a salt thereof.Join the waitlist — get patent alerts
Track US2015239849A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.